Epidemiology and etiopathogenesis of pituitary adenomas

Journal of Neuro-Oncology

Volumn 117, Issue 3, 2014, Pages 379-394

  Aflorei, Elena D ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Incidence; Oncogenes; Pituitary adenoma; Prevalence; Tumour suppressors

Indexed keywords

GROWTH FACTOR; HYPOPHYSIS HORMONE; MICRORNA;

AGE; ASYMPTOMATIC DISEASE; AUTOPSY; CANCER REGISTRY; CELL CYCLE; COMPRESSION; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GAIN OF FUNCTION MUTATION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CARCINOMA; INCIDENCE; LOSS OF FUNCTION MUTATION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT REFERRAL; POPULATION RESEARCH; PREVALENCE; RACE DIFFERENCE; RADIODIAGNOSIS; REVIEW; SEX DIFFERENCE; SOMATIC MUTATION; SPACE OCCUPYING EFFECT; SYMPTOM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; GENETICS; PITUITARY NEOPLASMS;

HUMANS; PITUITARY NEOPLASMS;

EID: 84901286734     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1354-5     Document Type: Review

References (122)

1. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341-353. doi:10.1227/01.NEU.0000223437.51435.6E
2. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 85(4):1420-1425. doi:10.1210/jc.85.4.1420
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14(Suppl 5):v1-49. doi:10.1093/neuonc/nos218
4. Shibui S (2012) The present status and trend of brain tumors based on the data of the Brain Tumor Registry of Japan. Brain Nerve 64(3):286-290
5. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 3(3):152-158. doi:10.1093/neuonc/3.3.152
6. Couldwell WT, Cannon-Albright L (2010) A heritable predisposition to pituitary tumors. Pituitary 13(2):130-137. doi:10.1007/s11102-009-0212-0
7. Costello RT (1936) Subclinical adenoma of the pituitary gland. Am J Pathol 12(2):205-216
8. Chambers EF, Turski PA, LaMasters D, Newton TH (1982) Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology 144(1):109-113
9. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613-619. doi:10.1002/cncr.20412
10. Nammour GM, Ybarra J, Naheedy MH, Romeo JH, Aron DC (1997) Incidental pituitary macroadenoma: a population-based study. Am J Med Sci 314(5):287-291
11. Yue NC, Longstreth WT Jr, Elster AD, Jungreis CA, O'Leary DH, Poirier VC (1997) Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology 202(1):41-46
12. Hartwigsen G, Siebner HR, Deuschl G, Jansen O, Ulmer S (2010) Incidental findings are frequent in young healthy individuals undergoing magnetic resonance imaging in brain research imaging studies: a prospective single-center study. J Comput Assist Tomogr 34(4):596-600. doi:10.1097/RCT.0b013e3181d9c2bb
13. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, van der Lugt A (2007) Incidental findings on brain MRI in the general population. N Engl J Med 357(18):1821-1828. doi:10.1056/ NEJMoa070972
14. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(4):894-904. doi:10.1210/jc.2010-1048
15. Clayton RN (1999) Sporadic pituitary tumours: from epidemiology to use of databases. Baillieres Best Pract Res Clin Endocrinol Metab 13(3):451-460
16. Ambrosi B, Faglia G (1991) Epidemiology of pituitary tumors. In: Faglia G, Ambrosi B, Travalini P, Spada A, Beck-Peccoz P (eds) Pituitary adenomas: new trends in basic and clinical research. Elsevier Science, Amsterdam, pp 159-168
17. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocr Metab 91(12):4769-4775. doi:10.1210/jc.2006- 1668
18. Fontana E, Gaillard R (2009) Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse 5(223):2172-2174
19. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377-382. doi:10.1016/j.ccr.2006.04.024
20. Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 95(9):4268-4275. doi:10.1210/jc.2010-0537
21. Gruppetta M, Mercieca C, Vassallo J (2012) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. doi:10.1007/s11102-012-0454-0
22. Daly AF, Cogne M, Tabarin A, Murat A, Delemer B, Luger A, Gaillard R, Colao A, Harris AG, Herlocu MC, Petrossians P, Beckers A (2007) The epidemiology of pituitary tumors: Results of an international collaborative study. In: The endocrine society annual meeting 2007, Toronto, Canada
23. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69(3):432-435. doi:10.1111/j.1365-2265.2008. 03221.x
24. Gold EB (1981) Epidemiology of pituitary adenomas. Epidemiol Rev 3:163-183
25. Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41(3):359-364. doi:10.1111/j.1365- 2265.1994.tb01849.x
26. Webb C, Prayson RA (2008) Pediatric pituitary adenomas. Arch Pathol Lab Med 132(1):77-80. doi:10.1043/1543-2165(2008)132[77:PPA]2.0.CO;2
27. Teramoto A, Hirakawa K, Sanno N, Osamura Y (1994) Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 193(1):161-164
28. Heshmat MY, Kovi J, Simpson C, Kennedy J, Fan KJ (1976) Neoplasms of the central nervous system: incidence and population selectivity in the Washington DC, metropolitan area. Cancer 38(5):2135-2142
29. McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA (2011) Demographic differences in incidence for pituitary adenoma. Pituitary 14(1):23-30. doi:10.1007/s11102-010-0253-4
30. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D (1994) H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 78(4):842-846. doi:10.1210/jc.78.4.842
31. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195-208. doi:10.3171/jns.2002.96.2.0195
32. Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7
33. Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD (1993) Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 76(2):529-533. doi:10.1210/jc.76.2.529
34. Lee W, Cheung AS, Freilich R (2012) TSH-secreting pituitary carcinoma with intrathecal drop metastases. Clin Endocrinol (Oxf) 76(4):604-606. doi:10.1111/j.1365-2265.2011.04288.x
35. Heaney AP (2011) Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649-3660. doi:10.1210/jc.2011-2031
36. Morokuma H, Ando T, Hayashida T, Horie I, Inoshita N, Murata F, Ueki I, Nakamura K, Imaizumi M, Usa T, Kawakami A (2012) A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. Case Rep Endocrinol 2012:645914. doi:10.1155/2012/645914
37. Kovacs GL, Goth M, Rotondo F, Scheithauer BW, Carlsen E, Saadia A, Hubina E, Kovacs L, Szabolcs I, Nagy P, Czirjak S, Hanzely Z, Kovacs K, Horvath E, Korbonits M (2013) ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Invest 43(1):20-26. doi:10.1111/eci.12010
38. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089-3099. doi:10.1210/jc.2004-2231
39. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804-812. doi:10.1002/(SICI) 1097-0142(19970215)79:4〈804::AID-CNCR18〉3.0.CO;2-3
40. Kars M, Roelfsema F, Romijn JA, Pereira AM (2006) Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155(4):523-534. doi:10.1530/eje.1.02268
41. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95(4):1708-1716. doi:10.1210/jc.2009-1191
42. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14(3):887-900. doi:10.1677/ERC-07-0062
43. Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17(2):361-371. doi:10.1677/ERC-10-0018
44. Potter VR (1980) Initiation and promotion in cancer formation: the importance of studies on intercellular communication. Yale J Biol Med 53(5):367-384
45. Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126. doi:10.1146/annurev.pathol.4.110807.092259
46. Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, Vanderpump M, Simpson D, Bicknell J, Farrell WE (2000) Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 6(10):3973-3982
47. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE (1995) Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 136(10):4479-4488. doi:10.1210/en.136.10.4479
48. Pellegrini I, Barlier A, Gunz G, Figarella-Branger D, Enjalbert A, Grisoli F, Jaquet P (1994) Pit-1 gene expression in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 79(1):189-196. doi:10.1210/jc.79.1. 189
49. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, Vidal S, Kovacs K, Raz A, Lloyd RV (2003) Differential expression of galectin-3 in pituitary tumors. Cancer Res 63(9):2251-2255
50. Takino H, Herman V, Weiss M, Melmed S (1995) Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80(5):1733-1738. doi:10.1210/jc.80.5.1733
51. Gadelha MR, Trivellin G, Hernández-Ramírez LC, Korbonits M (2013) Genetics of pituitary adenomas. Front Horm Res 41:111-140. doi:10.1159/000345673
52. Spada A, Vallar L (1992) G-protein oncogenes in acromegaly. Horm Res 38(1-2):90-93. doi:10.1159/000182498
53. Levy A, Lightman S (2003) Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 24(2):94-127. doi:10.1016/S0091- 3022(03)00012-8
54. Tada M, Kobayashi H, Moriuchi T (1999) Molecular basis of pituitary oncogenesis. J Neurooncol 45(1):83-96. doi:10.1023/A:1006390306336
55. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, Klibanski A (1994) ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocr Metab 78(1):89-93. doi:10.1210/jc.78.1.89
56. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL (1992) Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74(4):914-919. doi:10.1210/jc.74.4.914
57. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820-823
58. Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi ML (2012) The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit". PLoS One 7(6):e39767. doi:10.1371/journal.pone.0039767
59. Woloschak M, Yu A, Xiao J, Post KD (1996) Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int J Cancer 67(1):16-19. doi:10.1002/(SICI)1097-0215(19960703)67:1〈16:AID- IJC4〉3.0.CO;2-2
60. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A (2002) Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87(3):1262-1267. doi:10.1210/jc.87.3.1262
61. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A (2010) Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151(3):939-947. doi:10.1210/en.2009-0657
62. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J (2011) Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21(5):533-543. doi:10.1111/j.1750-3639.2011.00476.x
63. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359(6393):295-300. doi:10.1038/359295a0
64. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85(5):721-732
65. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM (2005) Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res 65(22):10214-10222. doi:10.1158/0008-5472.CAN-05-0884
66. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143(1):R1-R6. doi:10.1530/eje.0.143R001
67. Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5):257-266. doi:10.1038/nrendo.2011.40
68. Kirsch M, Morz M, Pinzer T, Schackert HK, Schackert G (2009) Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosom Cancer 48(2):143-154. doi:10.1002/gcc.20621
69. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y (1998) CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12(18):2899-2911. doi:10.1101/gad.12.18.2899
70. Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11(4):433-441. doi:10.1210/me.11.4.433
71. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM (2003) The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 148(2):203-211. doi:10.1530/eje.0.1480203
72. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4):536-543. doi:10.1111/j.1365-2265.2006.02630.x
73. Heaney AP, Melmed S (2000) New pituitary oncogenes. Endocr Relat Cancer 7(1):3-15. doi:10.1677/erc.0.0070003
74. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84(2):761-767. doi:10.1210/jc.84.2.761
75. Bazina M, Vukojevic K, Roje D, Saraga-Babic M (2009) Influence of growth and transcriptional factors, and signaling molecules on early human pituitary development. J Mol Histol 40(4):277-286. doi:10.1007/s10735-009-9239-9
76. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109(1):69-78. doi:10.1172/JCI14036
77. Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, Petrangeli E, Losa M, Stalla GK, Pagotto U (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183(2):385-394. doi:10.1677/joe.1.05616
78. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal TR, Balsari A, Spano P (1993) Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90(17):7961-7965
79. Shorts-Cary L, Xu M, Ertel J, Kleinschmidt-Demasters BK, Lillehei K, Matsuoka I, Nielsen-Preiss S, Wierman ME (2007) Bone morphogenetic protein and retinoic acid-inducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion. Endocrinology 148(3):967-975. doi:10.1210/en.2006-0905
80. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, Helin K, Croce CM, Fusco A (2006) HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9(6):459-471. doi:10.1016/j.ccr.2006.04.024
81. Ahtiainen P, Sharp V, Rulli SB, Rivero-Muller A, Mamaeva V, Roytta M, Huhtaniemi I (2010) Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr-Relat Cancer 17(3):611-621. doi:10.1677/ERC-10-0016
82. Palmieri D, Valentino T, De Matino I, Esposito F, Cappabianca P, Wierinckx A, Vitiello M, Lombardi G, Colao A, Trouillas J, Pierantoni GM, Fusco A, Fedele M (2012) PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer 19(2):123-135. doi:10.1530/ERC-11-0135
83. Zatelli MC, degli Uberti EC (2008) MicroRNAs and possible role in pituitary adenoma. Semin Reprod Med 26(6):453-460. doi:10.1055/s-0028-1096125
84. Sivapragasam M, Rotondo F, Lloyd RV, Scheithauer BW, Cusimano M, Syro LV, Kovacs K (2011) MicroRNAs in the human pituitary. Endocr Pathol 22(3):134-143. doi:10.1007/s12022-011-9167-6
85. Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Patocs A, Grossman AB, Korbonits M (2012) MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am J Physiol Endocrinol Metab 303(6):E708-E719. doi:10.1152/ajpendo.00546.2011
86. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390-2401. doi:10.1210/jc.2007-2611
87. Beckers A, Daly AF (2007) The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 157(4):371-382. doi:10.1530/EJE-07-0348
88. Moy J, Lawson D (1992) Temporal effects of estradiol and diethylstilbestrol on pituitary and plasma prolactin levels in ovariectomized Fischer 344 and Holtzman rats: a comparison of radioimmunoassay and Nb2 lymphoma cell bioassay. Proc Soc Exp Biol Med 200(4):507-513
89. Holtzman S, Stone JP, Shellabarger CJ (1979) Influence of diethylstilbestrol treatment on prolactin cells of female ACI and Sprague-Dawley rats. Cancer Res 39(3):779-784
90. Wildi-Runge S, Bahubeshi A, Carret A, Crevier L, Robitaille Y (2011) New phenotype in the familial DICER1 tumor syndrome: pituitary blastoma presenting at age 9 months. Endocr Rev 32(03):P1-P777
91. Denes J, Swords FM, Xekouki P, Kumar AV, Maher ER, Ferscht N, Grieve J, Baldeweg SE, Stratakis CA, Korbonits M (2012) Familial pituitary adenoma and paraganglioma syndrome - a novel type of multiple endocrine neoplasia. Endocr Rev 33(04):OR41-OR42
92. Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nesterova M, de la Luz SM, Matro J, Ball E, Azevedo M, Horvath A, Lyssikatos C, Quezado M, Patronas N, Ferrando B, Pasini B, Lytras A, Tolis G, Stratakis CA (2012) Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab 97(3):E357-E366. doi:10.1210/jc.2011-1179
93. Varsavsky M, Sebastian-Ochoa A, Torres VE (2013) Coexistence of a pituitary macroadenoma and multicentric paraganglioma: a strange coincidence. Endocrinol Nutr 60(3):154-156. doi:10.1016/j.endonu.2012.02.009
94. Brahma A, Heyburn P, Swords F (2009) Familial prolactinoma occurring in association with SDHB mutation positive paraganglioma. Endocrine 19:239
95. Coire CI, Smyth HS, Rosso D, Horvath E, Kovacs K (2010) A double pituitary adenoma presenting as a prolactin-secreting tumor with partial response to medical therapy: case report. Endocr Pathol 21(2):135-138. doi:10.1007/s12022-009-9104-0
96. Kurozumi K, Tabuchi A, Ono Y, Tamiya T, Ohmoto T, Furuta T, Hamasaki S (2002) Pituitary adenoma associated with neurofibromatosis type 1: case report. Neurol Surg 30(7):741-745
97. Drimmie FM, MacLennan AC, Nicoll JA, Simpson E, McNeill E, Donaldson MD (2000) Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol (Oxf) 53(4):535-538
98. Barberis M, Gambacorta M, Versari P, Filizzolo F (1979) About a case of Recklinghausen's disease associated with pituitary adenoma (author's transl). Pathologica 71(1012):265-272
99. Boudin G, Pepin B, Vernant CL (1970) Multiple tumours of the nervous system in Recklinghausen's disease. An anatomo-clinical case with chromophobe adenoma of the pituitary gland. Presse Med 78(32):1427-1430
100. Hartemann P, Schmitt J, Arnould G, Kissel P (1964) Acromegaly and Recklinghausen's neuro-fibromatosis. Apropos of 10 cases. Ann Endocrinol 25:601-618
101. Korbonits M, Storr H, Kumar AV (2012) Familial pituitary adenomas - who should be tested for AIP mutations? Clin Endocrinol (Oxf) 77(3):351-356. doi:10.1111/j.1365-2265.2012.04445.x
102. Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24(3):355-370. doi:10.1016/j.beem.2010.07.003
103. Lips CJ, Vasen HF, Lamers CB (1984) Multiple endocrine neoplasia syndromes. Crit Rev Oncol Hematol 2(2):117-184
104. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ (2006) Germline mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103(42):15558-15563. doi:10.1073/pnas.0603877103
105. Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocr Metab 94(5):1826-1834. doi:10.1210/jc.2008- 2083
106. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, de Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A (2006) Clinical characterization of familial isolated pituitary adenomas. J Clin Endocr Metab 91(9):3316-3323. doi:10.1210/jc.2005-2671
107. Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2010) Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab 21(7):419-427. doi:10.1016/j.tem.2010.02.007
108. Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ, Howlett TA, Levy MJ, Orme SM, Akker SA, Abel RL, Grossman AB, Burger J, Ellard S, Korbonits M (2011) AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 364(1):43-50. doi:10.1056/NEJMoa1008020
109. Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239-277. doi:10.1210/er.2012-1013
110. Stratakis CA, Horvath A (1993) Carney complex. GeneReviews, Seattle
111. Asa SL, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzalez-Manchon C, Vale W (1992) Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology 131(5):2083-2089
112. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM (1988) Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 2(7):606-612
113. Sano T, Asa SL, Kovacs K (1988) Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev 9(3):357-373. doi:10.1210/edrv-9-3-357
114. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, Kovacs K (1982) Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest 70(5):965-977
115. Sugiyama K, Kimura M, Abe T, Ikezawa Y, Manaka H, Yamatani K, Tominaga M, Sasaki H, Misawa T (1996) Hyperadrenocorticotropinemia in a patient with Addison's disease after treatment with corticosteroids. Intern Med 35(7):555-559
116. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 335(7621):651. doi:10.1136/bmj.39289.649410.55
117. Gorbman A (1950) Functional and structural changes consequent to high dosages of radioactive iodine. J Clin Endocrinol Metab 10(10):1177-1191
118. Ueno M, Inano H, Onoda M, Murase H, Ikota N, Kagiya TV, Anzai K (2009) Modification of mortality and tumorigenesis by tocopherol-mono-glucoside (TMG) administered after X irradiation in mice and rats. Radiat Res 172(4):519-524. doi:10.1667/RR1695.1
119. Johnson KA, Gorzinski SJ, Bodner KM, Campbell RA, Wolf CH, Friedman MA, Mast RW (1986) Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol 85(2):154-168. doi:10.1016/0041-008X(86)90109-2
120. Svensson K, Abramsson L, Becker W, Glynn A, Hellenas KE, Lind Y, Rosen J (2003) Dietary intake of acrylamide in Sweden. Food Chem Toxicol 41(11):1581-1586. doi:10.1016/S0278-6915(03)00188-1
121. Cannavo S, Ferrau F, Ragonese M, Curto L, Torre ML, Magistri M, Marchese A, Alibrandi A, Trimarchi F (2010) Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol 163(4):509-513. doi:10.1530/EJE-10-0465
122. Pesatori AC, Baccarelli A, Consonni D, Lania A, Beck-Peccoz P, Bertazzi PA, Spada A (2008) Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur J Endocrinol 159(6):699-703. doi:10.1530/EJE-08- 0593